Daiichi-Sankyo (South Korea)

Recent papers from Daiichi-Sankyo (South Korea)

1. Intracranial Haemorrhage and Haemorrhagic Stroke in Patients with Atrial Fibrillation on Edoxaban in ETNA-AF-EuropeJournal of Clinical Medicine · 2026
2. DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLCFuture Oncology · 2026
3. Incorporating estimands into meta-analyses of clinical trialsResearch Synthesis Methods · 2026
4. Aligning Estimands to Strengthen the Credibility of Network Meta-Analysis: Implications for Indirect Treatment ComparisonsStatistics in Biopharmaceutical Research · 2026
5. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3 -ITD–negative acute myeloid leukemiaFuture Oncology · 2026
6. From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across EuropeEP Europace · 2026
7. Predictors for non-persistence to edoxaban in Asian patients with atrial fibrillation: 2-year follow-up data from the ETNA-AF programmeEP Europace · 2026
8. Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and CostsJournal of health economics and outcomes research · 2026
9. Integrated spatial transcriptomics, single-nucleus RNA sequencing, and histopathology to reveal immune-suppressive niches in colorectal cancer liver metastases.Journal of Clinical Oncology · 2026
10. Additional health-related quality of life (HRQoL) analysis from DESTINY-Gastric04 (DG-04), a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA).Journal of Clinical Oncology · 2026
11. Trastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients (pts) with human epidermal growth factor receptor 2 (HER2)–expressing ovarian cancer (OC): Results from the DESTINY-Ovarian01 (DO-01/ENGOT-ov89/GOG-3112/APGOT-OV13) safety run-in (SRI).Journal of Clinical Oncology · 2026
12. TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinomaFuture Oncology · 2026
13. Characterization of human intestinal organoid-derived monolayers under air-liquid interface culture for pharmacokinetics evaluationDrug Metabolism and Disposition · 2026
14. Lipid management in high cardiovascular risk patients in France: a comparison with rest of Europe patients from 1-year follow-up of SANTORINISHILAP Revista de lepidopterología · 2026
15. Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE SubanalysisJournal of the American Heart Association · 2026
16. Ischemic and Bleeding Events After Early Initiation of Direct Oral Anticoagulants for Acute Intracranial Hemorrhage With Non-Valvular Atrial Fibrillation　― A Multicenter Prospective Registry ―Circulation Journal · 2026
17. Abstract PS5-08-14: Destiny-breast respond her2-low europe: description of first enrolled patients in the non-interventional study of t-dxd in her2-low metastatic breast cancerClinical Cancer Research · 2026
18. Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparisonFrontiers in Oncology · 2026
19. Comparing machine learning models with established risk scores in predicting bleeding and ischaemic stroke in patients with atrial fibrillation undergoing transcatheter aortic valve implantationEuropean Heart Journal · 2025
20. The 2024 ESC Guidelines for the Management of Atrial Fibrillation serve physicians well but leave a few questions unanswered: a social media-based poll of 433 European and Asian physiciansEuropean Heart Journal · 2025